Express News | Morgan Stanley Reports 10.3% Passive Stake in Arbutus Biopharma Corp as of May 31- SEC Filing

BreakingsJun 11 04:54

Express News | HC Wainwright & Co. has reiterated its buy rating for arbutus biopharma (ABUS.US), with a target price adjusted from $5.00 to $5.00.

BreakingsJun 7 23:30

Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4

Chardan Capital analyst Keay Nakae maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.2% an

Futu NewsJun 7 10:32

Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk

Arbutus Biopharma Corporation (ABUS) is currently at $3.33, down $0.30 or 8.26% --On pace for largest percent decrease since April 25, 2023, when it fell 12.46% --Currently down two of the past thre

Dow JonesJun 7 02:54

Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants w

BenzingaJun 6 23:16

Express News | Treatment With Arbutus’ Imdusiran and Vtp-300 Achieves Statistical Significance in Lowering Hbsag Levels

BreakingsJun 6 23:15